Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Based on in vitro data, coadministration with inhibitors of organic anion transporting polypeptide 1B3 (OATP1B3) may increase the plasma concentrations of taurursodiol (ursodoxicoltaurine). Clinical and pharmacokinetic data are currently lacking.

MANAGEMENT: Concomitant use of taurursodiol and OATP1B3 inhibitors should be avoided.

Food may affect the absorption of sodium phenylbutyrate. A high-fat, high-calorie meal (approximately 800 to 1000 calories; 500 to 600 calories from fat, 250 calories from carbohydrate, 150 calories from protein) has been shown to reduce the absorption of sodium phenylbutyrate, although it is unknown what impact this may have on the overall effectiveness of the medication. The manufacturer recommends taking sodium phenylbutyrate before a meal or snack. This is especially important if you weigh less than 70 kg (approximately 154 pounds). Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.